Clover Corporation Ltd
ASX:CLV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clover Corporation Ltd
ASX:CLV
|
AU |
|
HitGen Inc
SSE:688222
|
CN |
|
XANO Industri AB
STO:XANO B
|
SE |
Clover Corporation Ltd
Clover Corp. Ltd. is engaged in research and product development of food supplements, pharmaceutical and nutraceuticals. The company is headquartered in Melbourne, Victoria and currently employs 53 full-time employees. The Company’s geographical segments include Australia/New Zealand, Asia, Europe and America. The firm is also engaged in the production of encapsulated powders, and the research and product development of functional food and infant nutrition ingredients. The company focuses on developing nutrients for use in foods or as nutritional supplements. The firm provides lipid-based ingredients for the food industry. The company focuses on the delivery of bioactive ingredients using encapsulation technology to produce ready-to-blend products containing tuna oil and other nutritional lipids. The company uses tuna oil, which has docosahexaenoic acid (DHA) for brain, nerve and eye tissue development in babies and infants. The company has a technology license for the encapsulation of marine and algal oils. The firm has a manufacturing plant for tuna oils and related products in Altona, Victoria.
Clover Corp. Ltd. is engaged in research and product development of food supplements, pharmaceutical and nutraceuticals. The company is headquartered in Melbourne, Victoria and currently employs 53 full-time employees. The Company’s geographical segments include Australia/New Zealand, Asia, Europe and America. The firm is also engaged in the production of encapsulated powders, and the research and product development of functional food and infant nutrition ingredients. The company focuses on developing nutrients for use in foods or as nutritional supplements. The firm provides lipid-based ingredients for the food industry. The company focuses on the delivery of bioactive ingredients using encapsulation technology to produce ready-to-blend products containing tuna oil and other nutritional lipids. The company uses tuna oil, which has docosahexaenoic acid (DHA) for brain, nerve and eye tissue development in babies and infants. The company has a technology license for the encapsulation of marine and algal oils. The firm has a manufacturing plant for tuna oils and related products in Altona, Victoria.
Revenue: Record H1 revenue of $44.1 million, up $6.5 million versus the prior half, driven by new customers and higher sales from existing customers.
Margins: Gross profit rose to 35.6% (from 30.4% at FY'25 year‑end), supporting EBITDA of $6.9 million (up $2.6 million).
Profitability: NPAT was $4.2 million, up $1.8 million, and return on sales for the period was 9.6% (annualized ~11.6%).
Balance sheet: Cash of $10.3 million and no bank debt after repaying borrowings; inventory increased by $10.2 million to support strong demand.
Guidance: FY'26 revenue guidance of $92 million to $96 million, with management expecting H2 to be stronger than H1 assuming stable geopolitics and supply chains.
Strategic progress: Vertical integration (Ecuador crude oil facility supplying ~30% of period oil volumes) and Melody Dairies (43.9% ownership) are contributing to supply security and cost/quality benefits.
New products: CholineXcel powdered choline is in customer trials (IP expected July); management expects initial revenue next financial year and is scaling packaging/manufacturing capacity.
